Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC
Chenying Li, Lei Dong, Rui Su, et al.
Haematologica (2019) Vol. 105, Iss. 1, pp. 148-160
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Natural Products as Anticancer Agents: Current Status and Future Perspectives
Abid Naeem, Pengyi Hu, Ming Yang, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8367-8367
Open Access | Times Cited: 258
Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Jiawei Zhang, Yichao Gan, Hongzhi Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 79
Homoharringtonine: mechanisms, clinical applications and research progress
Wen Wang, Lan He, Ting Lin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 3
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen Chen, Zehua Wang, Yi Ding, et al.
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 12, pp. 326-326
Open Access | Times Cited: 41
Unraveling the therapeutic potential of natural products in the prevention and treatment of leukemia
Harsh Goel, Rahul Kumar, Pranay Tanwar, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114351-114351
Open Access | Times Cited: 24
TET1: The epigenetic architect of clinical disease progression
Keyvan Jabbari, Ali Khalafizadeh, Mahboubeh Sheikhbahaei, et al.
Genes & Diseases (2025), pp. 101513-101513
Open Access | Times Cited: 1
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, et al.
Blood (2021) Vol. 139, Iss. 6, pp. 907-921
Open Access | Times Cited: 55
Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation
Cheng Zou, Wenchao Li, Yuanzhen Zhang, et al.
Science Advances (2024) Vol. 10, Iss. 14
Open Access | Times Cited: 7
Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers
Ammad Ahmad Farooqi, Humaira Naureen, Rabbia Zahid, et al.
Pharmacological Research (2021) Vol. 172, pp. 105784-105784
Closed Access | Times Cited: 41
Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids
Mounir Tilaoui, Hassan Aît Mouse, Abdelmajid Zyad
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 39
Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia
Yiling Wang, Yan Yang, Xi Zheng, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Recent advances in natural therapeutic approaches for the treatment of cancer
Xuejun Wang, Jinyang Chen, Luo‐Qin Fu, et al.
Journal of Chemotherapy (2020) Vol. 32, Iss. 2, pp. 53-65
Closed Access | Times Cited: 39
The DNA methylation landscape of hematological malignancies: an update
Pedro Blecua, Laura Martinez‐Verbo, Manel Esteller
Molecular Oncology (2020) Vol. 14, Iss. 8, pp. 1616-1639
Open Access | Times Cited: 39
Phytochemical Loaded Nanovehicles of Biopolymer for Breast Cancer: A Systemic Review
Vivek P. Chavda, Suneetha Vuppu, Rajashri Bezbaruah, et al.
Clinical Complementary Medicine and Pharmacology (2023) Vol. 3, Iss. 4, pp. 100114-100114
Open Access | Times Cited: 13
Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma
Man Zhu, Zhengyan Gong, Qing Wu, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 8
Open Access | Times Cited: 30
Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay
Jingrong Zhao, Zhelin Li, Ruchira Puri, et al.
Molecular Therapy — Nucleic Acids (2021) Vol. 27, pp. 304-318
Open Access | Times Cited: 24
Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia
Shanshan Suo, Dandan Zhao, Fenglin Li, et al.
Blood (2024) Vol. 144, Iss. 12, pp. 1343-1347
Closed Access | Times Cited: 3
A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance
Cong Fu, Lin Sun, Cuncheng Feng, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
Ruirui Wang, Qiang Wang, Jinzhuang Liao, et al.
JCI Insight (2025) Vol. 10, Iss. 6
Open Access
Importance of Plant Secondary Metabolites in Modern Therapy
Monica R. P. Rao, Isha Ghadge, S. M. Kulkarni, et al.
Reference series in phytochemistry (2025), pp. 25-55
Closed Access
TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment
Shuai Guo, Xue Bai, Sai Shi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10930-10930
Open Access | Times Cited: 23
Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest
Jiafeng Tang, Guoli Li, Tao Zhang, et al.
Archives of Biochemistry and Biophysics (2021) Vol. 700, pp. 108774-108774
Closed Access | Times Cited: 20
Protective Effect of 20(S)-Protopanaxadiol on D-Gal-Induced Cognitively Impaired Mice Based on Its Target Protein Brain-type Creatine Kinase
Hantao Zhang, Feiyan Chen, Shuyi Xu, et al.
Journal of Agricultural and Food Chemistry (2023) Vol. 71, Iss. 7, pp. 3484-3496
Closed Access | Times Cited: 7
Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking
Dieter Weichenhan, Anna Riedel, Charlotte Meinen, et al.
Leukemia (2023) Vol. 37, Iss. 5, pp. 1147-1150
Open Access | Times Cited: 7
Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets
Xinlong Gao, Xu Zuo, Tianjiao Min, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top